glp 1 drugs and gallstones Why are GLP-1 agonists being used to treat patients with nonalcoholic fatty liver disease? The relative risk of clinically

Description

Lawrence ECN, Guo M, Schwartz TD, et al

Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes

284 , E931E939 (2003)

Meta-Analyses and Real-World Evidence A 2021 meta-analysis of major CVOTs confirmed a 14% MACE reduction (HR 0.86, 95% CI 0.80-0.93) with GLP-1 agonists, with significant reductions in MI, stroke, cardiovascular death, and all-cause mortality [51]

Similar results were found in a clinical study in patients with T2DM, where administration of liraglutide, but not metformin, increased the relative abundance of Akkermansia , which is often associated with the improvement of gastric mucosa and also becomes severely depleted in diabetic patients [115]